SSR3

Across TCGA pan-cancer cohorts, SSR3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SSR3 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SSR3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SSR3 expression acts as an unfavorable survival marker.

BRCA, DLBC, and CESC are the cancer types where SSR3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.027	0.963	<.001	36	view →
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
CESC	OS	Median	All	0.152	0.875	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SSR3–BRCA (OS)

Open the BRCA breakdown →